
    
      A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in
      patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort
      (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' compared with Pulmicort
      (budesonide) Turbuhaler 200 μg twice daily plus terbutaline Turbuhaler 0.4 mg 'as needed'
    
  